Testing effectiveness (Phase 2)Study completedNCT00003110What this trial is testingBleomycin in Treating Patients With Non-Hodgkin's LymphomaWho this might be right forLymphoma Case Comprehensive Cancer Center 5
Testing effectiveness (Phase 2)Study completedNCT03010358What this trial is testingEntospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin LymphomaWho this might be right forAnemiaB-Cell Prolymphocytic LeukemiaGrade 1 Follicular Lymphoma+11 more Alexey Danilov, MD 24
Testing effectiveness (Phase 2)Active Not RecruitingNCT05182385What this trial is testingVenetoclax in Addition to Blinatumomab in Adult Patients With Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL)Who this might be right forALL, Recurrent, Adult Goethe University 30
Early research (Phase 1)Ended earlyNCT00019708What this trial is testingGeldanamycin Analogue in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's LymphomaWho this might be right forExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueNodal Marginal Zone B-cell LymphomaNon-Hodgkin Lymphoma+25 more National Cancer Institute (NCI) 45
Early research (Phase 1)Study completedNCT00734890What this trial is testingVandetanib and Bevacizumab in Treating Patients With Advanced Solid Tumors or LymphomaWho this might be right forLung CancerLymphomaLymphoproliferative Disorder+2 more National Institutes of Health Clinical Center (CC) 18
Not applicableEnded earlyNCT00904514What this trial is testingStudy of Previously Collected and Stored Tissue Samples From Patients Previously Enrolled in a Completed National Cancer Institute Clinical TrialWho this might be right forCancer National Institutes of Health Clinical Center (CC) 241
Testing effectiveness (Phase 2)Study completedNCT05008055What this trial is testingStudy of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin LymphomaWho this might be right forRelapsed or Refractory B-cell Non-Hodgkin Lymphoma AstraZeneca 30
Early research (Phase 1)Study completedNCT00040950What this trial is testingBiological Therapy Plus Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaWho this might be right forLymphoma Jonsson Comprehensive Cancer Center
Testing effectiveness (Phase 2)WithdrawnNCT01131247What this trial is testingPH2 Trial in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) With a Combination of Bendamustine & OfatumumabWho this might be right forChronic Lymphocytic Leukemia (CLL) Nevada Cancer Institute 37
Testing effectiveness (Phase 2)Ended earlyNCT04730349What this trial is testingBempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant CancerWho this might be right forEpendymomaEwing SarcomaHigh-grade Glioma+7 more Bristol-Myers Squibb 15
Testing effectiveness (Phase 2)Looking for participantsNCT05633615What this trial is testingTesting Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell LymphomaWho this might be right forDiffuse Large B-Cell LymphomaGrade 3b Follicular LymphomaPrimary Mediastinal (Thymic) Large B-Cell Lymphoma+4 more SWOG Cancer Research Network 396
Early research (Phase 1)Looking for participantsNCT05098613What this trial is testingPreliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL PatientsWho this might be right forNon-Hodgkin LymphomaB-cell Non-Hodgkin Lymphoma (B-NHL)Mantle Cell Lymphoma (MCL)+1 more University of Colorado, Denver 68
Testing effectiveness (Phase 2)UnknownNCT03265106What this trial is testingA Clinical Study Evaluating the Safety and Efficacy of BinD19 Treatment in Childhood R/R ALL and Lymphoma SubjectsWho this might be right forRelapsed B-cell Acute Lymphoblastic Leukemia, ChildhoodRefractory B-cell Acute Lymphoblastic Leukemia, ChildhoodRelapsed/Refractory B-cell Lymphoma, Childhood Shenzhen BinDeBio Ltd. 20
Very early researchLooking for participantsNCT07695012What this trial is testingCAR-T Cell Therapy for ALLWho this might be right forRelapsed Acute Lymphoblastic Leukemia (ALL) Dr. Zaineb Akram 10
Testing effectiveness (Phase 2)Ended earlyNCT01235793What this trial is testingThe Addition of Temozolomide to Conditioning for Autologous Transplantation in Relapsed & Refractory CNS LymphomaWho this might be right forB-Cell Lymphoma Originating in the CNS Cedars-Sinai Medical Center 11
Testing effectiveness (Phase 2)Looking for participantsNCT04941716What this trial is testingAcalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 TrialWho this might be right forRecurrent Chronic Lymphocytic LeukemiaRecurrent Small Lymphocytic LymphomaRefractory Chronic Lymphocytic Leukemia+1 more Fred Hutchinson Cancer Center 20
Testing effectiveness (Phase 2)UnknownNCT05436223What this trial is testingHuman CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory B-cell Non-Hodgkin's LymphomaWho this might be right forB-cell Non-Hodgkin's Lymphoma Hrain Biotechnology Co., Ltd. 100
Early research (Phase 1)Looking for participantsNCT06743503What this trial is testingUB-VV400 in Combination With Rapamycin in Relapsed or Refractory B-cell MalignanciesWho this might be right forLarge B-cell Lymphoma Nanjing IASO Biotechnology Co., Ltd. 70
Early research (Phase 1)UnknownNCT04861779What this trial is testingHSK29116 in Adults With Relapsed/Refractory B-cell MalignanciesWho this might be right forRelapsed/Refractory B-Cell Malignancies Haisco Pharmaceutical Group Co., Ltd. 156
Early research (Phase 1)Study completedNCT00109824What this trial is testingDecitabine With or Without Valproic Acid in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaWho this might be right forRecurrent Adult Burkitt LymphomaRecurrent Adult Diffuse Large Cell LymphomaRecurrent Mantle Cell Lymphoma National Cancer Institute (NCI) 42